AIM: To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease(CD).METHODS: We carried out a literature search in Pub Med, MEDLINE, EMBASE and the Cochr...AIM: To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease(CD).METHODS: We carried out a literature search in Pub Med, MEDLINE, EMBASE and the Cochrane Library to screen for citations from January 1990 to August2014. Data analysis was performed using Review Manager version 5.2.RESULTS: A total of 1340 patients from five studies were involved in this meta-analysis. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission with OR = 1.69, 95%CI: 1.37-2.09 and 1.84, 95%CI: 1.44-2.34, respectively. No significant difference was found between integrin antagonists and placebo treatments regarding their adverse reactions(OR = 1.07, 95%CI: 0.83-1.38) and serious adverse reactions(OR = 0.81, 95%CI: 0.57-1.15).CONCLUSION: The results prove the efficacy and safety of integrin antagonists for CD treatment, although the treatment strategies varied.展开更多
基金Supported by National Natural Science Foundation of China,No.81200279Medical-Engineering(Science)cross-Research Fund of Shanghai Jiao Tong University,No.YG2011MS29
文摘AIM: To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease(CD).METHODS: We carried out a literature search in Pub Med, MEDLINE, EMBASE and the Cochrane Library to screen for citations from January 1990 to August2014. Data analysis was performed using Review Manager version 5.2.RESULTS: A total of 1340 patients from five studies were involved in this meta-analysis. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission with OR = 1.69, 95%CI: 1.37-2.09 and 1.84, 95%CI: 1.44-2.34, respectively. No significant difference was found between integrin antagonists and placebo treatments regarding their adverse reactions(OR = 1.07, 95%CI: 0.83-1.38) and serious adverse reactions(OR = 0.81, 95%CI: 0.57-1.15).CONCLUSION: The results prove the efficacy and safety of integrin antagonists for CD treatment, although the treatment strategies varied.
